Mr Mrs Miss Ms Dr Other

Dr
David
Selby

Partner & Patent Attorney

Leeds Office Manchester Office

Chemistry

Telephone. +44(0) 113 233 0100
Mobile. +44(0) 758 599 7412
Email. dselby@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard
Linkedin

Experience

David's practice is predominantly in the areas of chemical and biomedical research tools, analytical instrumentation, pharmaceuticals, and cell culture technologies. David's experience in these areas includes GB and European patent prosecution, drafting and international portfolio management for large corporations, universities and spin-out companies. David also has significant experience in oppositions and appeals before the EPO. Other subject matter that falls within David's practice includes medical devices, nanotechnology and advanced materials.

David has a PhD in Chemistry, as well as a law degree from the University of New South Wales. His research experience included the construction of a novel mass spectrometer, and the application of mass spectrometry to proteomics and analysis of post-translational modification of proteins. His research experience thus covers development of instrumentation and methods of chemical analysis, through to characterisation of biological materials.

David qualified as a solicitor in Sydney, Australia, where he worked in IP litigation and has also qualified as a solicitor in England and Wales. David's practice draws on this combination of scientific and legal experience, with his understanding of enforcement and opposition informing his patent drafting and prosecution, and assisting David in providing commercially focused strategic advice in all areas of his practice.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BSC

BSc in Chemistry with Hons 1

LLB

Bachelors of laws, UNSW

PHD

Chemistry

Publications

HGF continues to grow with 7 new promotions

View publication online

Conferences: 2024

15-10-2024

Targeting protein degradation 4

Attended

Event details

CSR

David is a member of the Sustainability Focus Group at HGF which helps to promote sustainability at HGF

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us